Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes
Authors:
- 1 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (5) , 799-804
Abstract
Cardiovascular disease is the most important cause of morbidity and mortality in patients with type 2 diabetes. Endothelial dysfunction predicts cardiovascular outcome. Type 2 diabetes is characterized by endothelial dysfunction, which may be caused by dyslipidemia. Statin therapy restores endothelial function in hyperlipidemic patients. Therefore, we hypothesize a beneficial effect of atorvastatin on NO-dependent vasodilation in patients with type 2 diabetes and mild dyslipidemia (low density lipoproteins >4.0 mmol/L and/or triglycerides >1.8 mmol/L). We evaluated the effect of intensive lipid lowering (4 weeks of 80 mg atorvastatin once daily) on vasoreactivity in 23 patients with type 2 diabetes by using venous occlusion plethysmography. Twenty-one control subjects were matched for age, sex, body mass index, blood pressure, and smoking habits. The ratio of blood flows in the infused (measurement [M]) and noninfused (control [C]) arm was calculated for each recording (M/C ratio), and M/C% indicates the percentage change from the baseline M/C ratio. Serotonin-induced NO-dependent vasodilation was significantly blunted (52±30 versus 102±66 M/C%, P P P P P <0.05] mmol/L, respectively), no effect on NO-dependent (59±44 M/C%) and endothelium-independent (292±202 M/C%) vasodilation was demonstrated. These data suggest that intensive lipid lowering by atorvastatin has no effect on NO availability in forearm resistance arteries in type 2 diabetic patients. Other factors, such as hyperglycemia, may be a more important contributing factor regarding impaired vasoreactivity in this patient group.Keywords
This publication has 37 references indexed in Scilit:
- Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effectsKidney International, 2000
- Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants.Diabetes Care, 1999
- Effect of oral vitamin E (α‐tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitusDiabetic Medicine, 1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetesDiabetic Medicine, 1997
- Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitusJACC, 1996
- Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1996
- Serotonin-Induced Vasodilatation in the Human Forearm Is Mediated by the “Nitric Oxide-Pathway”Journal of Cardiovascular Pharmacology, 1993
- Hypercholesterolemia increases endothelial superoxide anion production.Journal of Clinical Investigation, 1993
- Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemiaThe Lancet, 1992